Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05835167
Other study ID # 2022-GSP-GG-23
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 5, 2023
Est. completion date May 4, 2035

Study information

Verified date April 2023
Source China National Center for Cardiovascular Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.


Description:

Coronary artery bypass grafting (CABG) has always been the gold standard for surgical treatment of coronary artery disease (CAD), especially for left main (LM) coronary disease, patients with high SYNTAX scores, and diabetes mellitus. By minimally invasive strategy, patients recover significantly faster in the early post-operative period. However, a prospective randomized controlled trials is needed to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG. Objectives: To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy. Study design: This is a prospective, multicenter, open-label, randomized controlled trial. We aim to randomize 260 patients undergoing isolated CABG to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China. We consecutively screen patients during the study enrollment period and seek informed consent from all eligible patients. Patients who give informed consent are randomly assigned to undergo inferior part-sternotomy CABG or full median sternotomy CABG by a central randomization system. An expert group composed of three doctors with CABG qualifications will develop a plan achieving complete revascularization by coronary angiography images before the operation, including the number and location of proximal and distal anastomoses. The actual bypass procedure will be recorded and compared with the preoperative plan. We will follow-up participants until 10 years after the operation. To reduce the variation among surgeons, we require that all CABG are performed by qualified surgeons. The surgeons in this study needs to have experience in at least 100 cases of full median sternotomy CABG, and at least 5 cases of inferior part-sternotomy CABG.The ethics committees at all 9 participating hospitals approved this study. Randomization A web-based central randomization system incorporated in the registration system is used for allocation (http://ccsr.cvs-china.com/). The randomization code with fixed block size is generated by SAS. Randomization is stratified by investigation center. When an eligible patient gives informed consent, the investigator logs in to the randomization webpage and obtain the random number along with treatment group (Inferior part-sternotomy or Full median sternotomy group) automatically distributed by the system after the basic patient information be confirmed. The statistician responsible for the randomization code and the staff who develops the Interactive Web-based Response (IWR) system are independent of each other. Intervention Surgical procedure.The patient is placed in the supine position. Standard intubation and hemodynamic monitoring are used. Heparinization is standardized for on-pump CABG. The surgeon is given discretion to ensure that his choice in surgery would ensure the patient´s safety (including which graft to use or the choice of anatomic regions to revascularize). The surgeries are performed with the usual methods of cardiopulmonary bypass (CPB) with aortic cross-clamp technique. Myocardial protection strategies include blood cardioplegia and moderate hypothermia. For both types of surgeries, an excellent exposure is required. Inferior part-sternotomy CABG.A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward. Remaining coronary bypassing techniques are same in both groups according to clinical practice and preference of the operator. Full median sternotomy CABG. A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw. Medication. All participants are prescribed dual antiplatelet therapy with aspirin 100 mg plus clopidogrel 75 mg daily from the first day post-CABG until 3 months post-operation. Prescription of other concomitant medications such as β-blockers, statins, and antihypertensive agents is determined by local surgeons according to ACC/AHA guidelines. The trial data will be analyzed on an intention-to-treat basis with patients included in the groups assigned at randomization, irrespective of future management and events.Demographic and clinical variables will be summarized as means (SDs) for continuous and counts (percentages) for categorical variables. Comparisons across the groups will be performed using a 2-tailed unpaired t test for continuous variables and the Pearson's χ2 test for categorical variables. A P value of less than 0.05 will be considered as statistically significant for all analyses. Clinical events committee. All clinical events including myocardial infarction, stroke, target lesion revascularization, and death will undergo central adjudication by an independent clinical events committee (CEC).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 260
Est. completion date May 4, 2035
Est. primary completion date May 4, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Patients who undergo primary isolated open-chest CABG with multi-vessel coronary disease(left main artery disease with right coronary artery disease,or three-vessel disease) Exclusion Criteria: 1. Single vessel disease, double vessel disease, left main artery disease without right coronary artery disease. 2. Concomitant cardiac surgeries(i.e. valve repair or replacement, Maze surgery, left ventricular repair due to ventricular aneurysm). 3. Redo CABG. 4. Emergent CABG. 5. Left ventricular ejection fraction(EF=35%). 6. Severe atherosclerosis of the ascending aorta. 7. Subjects tend to choose surgical approach (via full median sternotomy/inferior part-sternotomy) . 8. Malignant tumor or other severe systemic diseases. 9. Severe renal insufficiency (i.e. creatinine >200 µmol/L). 10. Contraindications for dual antiplatelet therapy, such as active gastroduodenal ulcer. 11. Participant of other ongoing clinical trials.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Inferior part-sternotomy
A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
Full median sternotomy
A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.

Locations

Country Name City State
n/a

Sponsors (9)

Lead Sponsor Collaborator
China National Center for Cardiovascular Diseases Baotou Central Hospital, Beijing Shijitan Hospital, Capital Medical University, Fuwai Yunnan Cardiovascular Hospital, Henan Provincial People's Hospital, Peking University International Hospital, Shenzhen Sun Yat-sen Cardiovascular Hospital, Tangshan Central Hospital, Xiamen Second Hospital

References & Publications (7)

Kleisli T, Cheng W, Jacobs MJ, Mirocha J, Derobertis MA, Kass RM, Blanche C, Fontana GP, Raissi SS, Magliato KE, Trento A. In the current era, complete revascularization improves survival after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2005 Jun;129(6):1283-91. doi: 10.1016/j.jtcvs.2004.12.034. — View Citation

Lapierre H, Chan V, Sohmer B, Mesana TG, Ruel M. Minimally invasive coronary artery bypass grafting via a small thoracotomy versus off-pump: a case-matched study. Eur J Cardiothorac Surg. 2011 Oct;40(4):804-10. doi: 10.1016/j.ejcts.2011.01.066. Epub 2011 Mar 9. — View Citation

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. No abstract available. Erratum In: Eur Heart J. 2019 Oct 1;40(37):3096. — View Citation

Ong AT, Serruys PW. Complete revascularization: coronary artery bypass graft surgery versus percutaneous coronary intervention. Circulation. 2006 Jul 18;114(3):249-55. doi: 10.1161/CIRCULATIONAHA.106.614420. No abstract available. — View Citation

Sohn SH, Kang Y, Kim JS, Paeng JC, Hwang HY. Impact of Functional vs Anatomic Complete Revascularization in Coronary Artery Bypass Grafting. Ann Thorac Surg. 2023 Apr;115(4):905-912. doi: 10.1016/j.athoracsur.2022.10.029. Epub 2022 Nov 9. — View Citation

Sun HS, Ma WG, Xu JP, Sun LZ, Lu F, Zhu XD. Minimal access heart surgery via lower ministernotomy: experience in 460 cases. Asian Cardiovasc Thorac Ann. 2006 Apr;14(2):109-13. doi: 10.1177/021849230601400206. — View Citation

Veiga Oliveira P, Madeira M, Ranchordas S, Marques M, Almeida M, Sousa-Uva M, Abecasis M, Neves JP. Complete surgical revascularization: Different definitions, same impact? J Card Surg. 2021 Dec;36(12):4497-4502. doi: 10.1111/jocs.15986. Epub 2021 Sep 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Complete revascularization rate immediately after surgery Most surgical groups have adopted the functional definition in their studies. We therefore elected to use a functional definition for complete revascularization in the present study. The coronary vascular tree was divided into 3 separate territories: the left anterior descending artery (LAD), the circumflex artery, and the right coronary artery (RCA).Functional completeness of revascularization is defined as all viable myocardial territories are reperfused, as at least one bypass graft for every diseased primary arterial territory Immediately after surgery
Secondary The harvest time of left Internal mammary artery (LIMA) It is defined as the time from skin incision to clamping of the distal part of the LIMA. During surgery
Secondary Aortic cross-clamp time During surgery
Secondary Overall operation time It is defined as the time from skin incision to skin sutured. During surgery
Secondary Intraoperative real-time blood flow at each anastomosis It was evaluated intraoperatively using ultrasound flow measurements. During surgery
Secondary The total amount of postoperative chest tube drainage This includes the amount of fluid of closed thoracic drainage or thoracentesis drainage due to pleural effusion during hospitalization. Up to 4 weeks
Secondary The graft patency rate by CTA at 5-7 days, 1 year, 3 years, 5 years, and 10 years after surgery Graft occlusion is detected by computed tomography angiography (CTA). Grafts are graded into three levels: A (excellent), B (fair), or C (occluded). Contrast filling of the grafts, anastomoses, and coronary arteries beyond the graft are considered in each assessment. Grade A indicates that the graft is patent with =50% stenosis. Grade B indicates that graft stenosis is >50% but not occluded. When a graft does not fill with contrast at all, it is considered Grade C and included with string sign found in any segment (including proximal and distal anastomotic site, and main trunk). Both of these findings are considered together and referred to as occlusion in the analysis.The patency rate of grafts = number of grafts in grades A and B/total number of bypass grafts. 1week after the surgery;10 years after surgery
Secondary The rate of major adverse cardiac or cerebrovascular events (MACCE) at 5-7 days, 1 year, 3 years, 5 years, and 10 years after surgery MACCE: cardiac death, myocardial infarction, stroke, repeat revascularization and hospitalization for heart failure.
Myocardial infarction (troponin values >10 times the 99th percentile of upper reference limit in association with new Q waves).
1week after the surgery;10 years after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT01850082 - Randomized Endo-Vein Graft Prospective N/A
Not yet recruiting NCT04657835 - Assessment of Atrial Cardiomyopathy Using MRI as a Predictor of Cardiac Post-Operative Atrial Fibrillation After Cardiac Surgery. N/A
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01528514 - Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study N/A
Completed NCT01378221 - VItamin D Metabolism in SEnescent Cardiac Surgery Patients N/A
Completed NCT00848796 - Comparative Study of Two Brands of Heparin Already on the Market N/A
Not yet recruiting NCT05552586 - Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery N/A
Completed NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Phase 2
Completed NCT00420667 - Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery N/A
Recruiting NCT04197700 - The PRESSURE CABG Cardiac Surgery Trial N/A
Not yet recruiting NCT06326996 - Thiamine Intervention and Coronary Artery Bypass Grafting N/A
Not yet recruiting NCT02732574 - Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery N/A
Completed NCT00903604 - Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery Phase 2
Completed NCT01182688 - Prospective Review of Procalcitonin After Cardiac Surgery N/A
Completed NCT02737215 - Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea N/A
Recruiting NCT03209414 - Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
Recruiting NCT05441358 - Assessment of Platelet Function in Patients Undergoing Open Heart Surgery
Recruiting NCT02400125 - China Cardiovascular Surgery Registry N/A
Terminated NCT00628264 - Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery Phase 2